ArticleThe British journal of surgery2025
The effect of weight change on death and cardiovascular events after Roux-en-Y gastric bypass.
Article in The British journal of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Outcomes and Recurrent Weight Gain 10 Years After Roux-en-Y Gastric Bypass, a Longitudinal Cohort Study.Obesity surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWeight changes after Roux-en-Y gastric bypass (RYGB) follow different trajectories, but the effects of different trajectories on death and cardiovascular events are largely unknown. The aim of the current study was therefore to evaluate the effects of weight changes after RYGB on cardiovascular events and mortality rate.
methodsThis cohort study included patients who underwent primary RYGB in Sweden from 2007 to 2018 with a complete registration of weight at baseline, at nadir weight loss and 5-year follow-up (n = 25 230) with a mean BMI of 42.1 ± 5.2 kg/m2, age 42.5 ± 11.2 years, and 19 420 (77%) women. Patients were stratified based on weight change from nadir weight loss. The main outcome measures were major cardiovascular event (MACE) or death.
resultsOver a mean follow-up of 10.6 years, 1276 patients experienced at least one episode of a MACE, and 707 died. An increased risk for death and MACE was seen in patients with continued weight loss after nadir (adjusted HR compared to recurrent weight gain of 0-20% of weight lost at nadir among patients who initially lost 20-35% total weight (TWL): 1.80 (1.41-2.31) and 1.62 (1.35-1.94) respectively), and for patients who experienced >50% recurrent weight gain from nadir (adjusted HR compared to patients with recurrent weight gained 0-20% TWL: 1.61 (1.07-2.43) and 1.48 (1.09-2.00) respectively).
conclusionContinued weight loss and significant recurrent weight gain after the initial weight nadir were both associated with a higher risk for MACE and death after RYGB. These should be considered non-desirable weight trajectories requiring further clinical evaluation and increased support.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.